{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T17:50:16Z","timestamp":1723398616970},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.2169\/internalmedicine.5665-20","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T22:05:29Z","timestamp":1604268329000},"page":"1101-1107","source":"Crossref","is-referenced-by-count":3,"title":["Anti-PM\/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement"],"prefix":"10.2169","volume":"60","author":[{"given":"Tatsuya","family":"Shimizu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzo","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirayasu","family":"Kai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Morito","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joichi","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yokosawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Okiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Denton CP, Khanna D. Systemic sclerosis. Lancet 390: 1685-1699, 2017.","DOI":"10.1016\/S0140-6736(17)30933-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hamaguchi Y. Autoantibodies and their clinical characteristics in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi (Jpn J Clin Immunol) 36: 139-147, 2013 (in Japanese, Abstract in English).","DOI":"10.2177\/jsci.36.139"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hamaguchi Y, Hasegawa M, Fujimoto M, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158: 487-495, 2008.","DOI":"10.1111\/j.1365-2133.2007.08392.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Brouwer R, Vree Egberts WT, Hengstman GJ, et al. Autoantibodies directed to novel components of the PM\/Scl complex, the human exosome. Arthritis Res 4: 134-138, 2002.","DOI":"10.1186\/ar389"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hanke K, Br\u00fcckner CS, D\u00e4hnrich C, et al. Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther 11: R22, 2009.","DOI":"10.1186\/ar2614"},{"key":"6","unstructured":"6. Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: Correlation with characteristic clinical features. Arthritis Res Ther 13: R172, 2011."},{"key":"7","unstructured":"7. D&apos;Aoust J, Hudson M, Tatibouet S, et al. Clinical and serologic correlates of anti-PM\/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 66: 1608-1615, 2014."},{"key":"8","unstructured":"8. Koschik RW 2nd, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30: S12-S16, 2012."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Marguerie C, Bunn CC, Copier J, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM\/Scl. Medicine (Baltimore) 71: 327-336, 1992.","DOI":"10.1097\/00005792-199211000-00001"},{"key":"10","unstructured":"10. Sato T, Hanaoka R, Ohshima M, et al. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: observations in a single hospital. Clin Exp Rheum 24: 454-455, 2006."},{"key":"11","unstructured":"11. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism Collaborative Initiative. Arthritis Rheum 65: 2737-2747, 2013."},{"key":"12","unstructured":"12. Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147: 391-398, 2011."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bhavsar SV, Carmona R. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. J Clin Rheumatol 20: 379-382, 2014.","DOI":"10.1097\/RHU.0000000000000167"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Zwettler U, Andrassy K, Waldherr R, Ritz E. Scleroderma renal crisis as a presenting feature in the absence of skin involvement. Am J Kidney Dis 22: 53-56, 1993.","DOI":"10.1016\/S0272-6386(12)70166-X"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Thomas CP, Nester CM, Phan AC, Sharma M, Steele AL, Lenert PS. Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome. Clin Kidney J 8: 698-701, 2015.","DOI":"10.1093\/ckj\/sfv101"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Batal I, Domsic RT, Shafer A, Medsger TA Jr, Kiss LP, Randhawa P, Bastacky S. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 40: 332-340, 2009.","DOI":"10.1016\/j.humpath.2008.08.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jacquier M, Mousson C, Rebibou JM, et al. Scleroderma renal crisis in a systemic sclerosis with anti-PM\/Scl antibodies. Kidney Int Rep 4: 1499-1502, 2019.","DOI":"10.1016\/j.ekir.2019.07.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mouthon L, Bussone G, Berezne A, et al. Scleroderma renal crisis. J Rheumatol 41: 1040-1048, 2014.","DOI":"10.3899\/jrheum.131210"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 40: 1257-1266, 1997.","DOI":"10.1002\/1529-0131(199707)40:7<1257::AID-ART10>3.0.CO;2-R"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37: 75-83, 1994.","DOI":"10.1002\/art.1780370111"},{"key":"21","unstructured":"21. Kaji K, Fertig N, Medsger Jr TA, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) 66: 575-584, 2014."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M. Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 17: 57, 2015.","DOI":"10.1186\/s13075-015-0573-x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hudson M, Pope J, Mahler M, et al. Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis. Arthritis Res Ther 14: R50, 2012.","DOI":"10.1186\/ar3763"},{"key":"24","unstructured":"24. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 28: 1573-1576, 2001."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590, 1980.","DOI":"10.1002\/art.1780230510"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/7\/60_5665-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:56:45Z","timestamp":1617422205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/7\/60_5665-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5665-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}